Year-to-date and Q3 2019 results

Conference call and webcast for investors and analysts 24 October 2019
Forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and AstraZeneca undertakes no obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things: the loss or expiration of, or limitations to, patents, marketing exclusivity or trademarks, or the risk of failure to obtain and enforce patent protection; effects of patent litigation in respect of IP rights; the impact of any delays in the manufacturing, distribution and sale of any of our products; the impact of any failure by third parties to supply materials or services; the risk of failure of outsourcing; the risks associated with manufacturing biologics; the risk that R&D will not yield new products that achieve commercial success; the risk of delay to new product launches; the risk that new products do not perform as we expect; the risk that strategic alliances and acquisitions, including licensing and collaborations, will be unsuccessful; the risks from pressures resulting from generic competition; the impact of competition, price controls and price reductions; the risks associated with developing our business in emerging markets; the risk of illegal trade in our products; the difficulties of obtaining and maintaining regulatory approvals for products; the risk that regulatory approval processes for biosimilars could have an adverse effect on future commercial prospects; the risk of failure to successfully implement planned cost reduction measures through productivity initiatives and restructuring programmes; the risk of failure of critical processes affecting business continuity; economic, regulatory and political pressures to limit or reduce the cost of our products; failure to achieve strategic priorities or to meet targets or expectations; the risk of substantial adverse litigation/government investigation claims and insufficient insurance coverage; the risk of substantial product liability claims; the risk of failure to adhere to applicable laws, rules and regulations; the risk of failure to adhere to applicable laws, rules and regulations relating to anti-competitive behaviour; the impact of increasing implementation and enforcement of more stringent anti-bribery and anti-corruption legislation; taxation risks; exchange rate fluctuations; the risk of an adverse impact of a sustained economic downturn; political and socio-economic conditions; the risk of environmental liabilities; the risk of occupational health and safety liabilities; the risk associated with pensions liabilities; the impact of failing to attract and retain key personnel and to successfully engage with our employees; the risk of misuse of social media platforms and new technology; and the risk of failure of information technology and cybercrime. Nothing in this presentation / webcast should be construed as a profit forecast.
Presenters

Pascal Soriot  
Executive Director and  
Chief Executive Officer

Dave Fredrickson  
Executive Vice President,  
Oncology Business Unit

Ruud Dobber  
Executive Vice President,  
BioPharmaceuticals Business Unit

Marc Dunoyer  
Executive Director and  
Chief Financial Officer

José Baselga  
Executive Vice President,  
Oncology R&D

Mene Pangalos  
Executive Vice President,  
BioPharmaceuticals R&D
Agenda

Overview

Oncology

BioPharmaceuticals, Emerging markets

Finance

Pipeline update, news flow

Closing and Q&A
YTD and Q3 2019: repeated strong sales growth
Investing in sustainable growth continued in R&D, SG&A

Business and financials

Product sales up by 17%; 18% in the third quarter
• Strong performance of new medicines¹ (+72%); $3.0bn incremental sales vs. YTD 2018
• Oncology (+54%), New CVRM² (+14%) and Respiratory (+13%)
• Emerging markets (+26%); broad-based performance across EMs

Total revenue up by 17%; broadly stable collaboration revenue
Core operating costs up by 6%; investing in sustainable growth
Core operating profit up by 42%; continuing operating leverage. Core EPS $2.61, including 22% tax rate

Guidance increased again for product sales; unchanged for core EPS³ (due to accelerating strategic transition, resulting in anticipated lower total of collaboration revenue and other operating income)

Focus on cash-flow generation whilst continuing to invest in high-growth opportunities and rich pipeline

Pipeline with unprecedented recent positive news flow; busy 2021 pipeline plans unveiled

1. Tagrisso, Imfinzi, Calquence, Farxiga, Brilinta, Lokelma, roxadustat, Fasenra, Bevespi and Breztri; absolute value at constant exchange rates (CER) and compared to YTD 2018  2. New Cardiovascular, Renal and Metabolism incorporating Diabetes, Brilinta, Lokelma and roxadustat  3. Earnings per share.

Absolute values and changes at CER (except core EPS) and for YTD 2019, unless otherwise stated. Guidance at CER.
**Q3 2019: unprecedented, positive updates**

**News-flow highlights from the late-stage pipeline**

### Pipeline news

<table>
<thead>
<tr>
<th><strong>Oncology</strong></th>
<th><strong>BioPharmaceuticals</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tagrisso</strong></td>
<td><strong>Farxiga/Forxiga</strong></td>
</tr>
<tr>
<td><em>Tagrisso</em></td>
<td>T2D7 CVOT8</td>
</tr>
<tr>
<td><em>Imfinzi + treme</em></td>
<td>HF3 CVOT</td>
</tr>
<tr>
<td><em>Lynparza</em></td>
<td>CKD10</td>
</tr>
<tr>
<td><em>trastuzumab deruxtecan</em></td>
<td>T2D</td>
</tr>
<tr>
<td><em>Calquence</em></td>
<td>CAD12/T2D CVOT</td>
</tr>
<tr>
<td><strong>trastuzumab deruxtecan</strong></td>
<td>anaemia of CKD; NDD12</td>
</tr>
<tr>
<td><strong>Calquence</strong></td>
<td>PT010</td>
</tr>
<tr>
<td><strong>trastuzumab deruxtecan</strong></td>
<td>COPD13 (ETHOS)</td>
</tr>
<tr>
<td><strong>Imfinzi + treme</strong></td>
<td>COPD</td>
</tr>
<tr>
<td><strong>Lynparza</strong></td>
<td>severe eosinophilic asthma; autoinjector and self-administration</td>
</tr>
<tr>
<td><strong>trastuzumab deruxtecan</strong></td>
<td>eosinophilic oesophagitis</td>
</tr>
<tr>
<td><strong>Calquence</strong></td>
<td>lupus (SLE14) (TULIP 2)</td>
</tr>
</tbody>
</table>

**regulatory approval (CN); met Phase III key secondary endpoint (OS3)**

**did not meet Phase III primary endpoint**

**regulatory submission acceptance (US, EU)**

**met Phase III primary endpoint**

**met Phase III primary endpoint**

**regulatory submission acceptance (US, JP)**

**Priority Review designation (US)**

**regulatory submission under review (US)**

**Breakthrough Therapy Designation (US)**

**regulatory approval (US, EU)**

**met Phase III primary endpoint**

**Fast Track designation (US)**

**Fast Track designation (US)**

**positive opinion (EU)**

**regulatory submission acceptance (US, EU)**

**regulatory approval (CN)**

**met Phase III primary endpoint**

**complete response letter (US)**

**met Phase III primary endpoint**

<table>
<thead>
<tr>
<th><strong>1. Non-small cell lung cancer</strong></th>
<th><strong>2. Substitution of threonine (T) with methionine (M) at position 790 of exon 20 mutation</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>3. Overall survival</strong></td>
<td><strong>4. Breast cancer susceptibility genes 1/2 mutation</strong></td>
</tr>
<tr>
<td><strong>5. Human epidermal growth factor receptor 2 positive</strong></td>
<td><strong>6. Chronic lymphocytic leukaemia</strong></td>
</tr>
<tr>
<td><strong>7. Type-2 diabetes</strong></td>
<td><strong>8. Cardiovascular (CV) outcomes trial</strong></td>
</tr>
<tr>
<td><strong>9. Heart failure</strong></td>
<td><strong>10. Chronic kidney disease</strong></td>
</tr>
<tr>
<td><strong>11. Coronary artery disease</strong></td>
<td><strong>12. Non dialysis-dependent patients</strong></td>
</tr>
<tr>
<td><strong>13. Chronic obstructive pulmonary disease</strong></td>
<td><strong>14. Systemic lupus erythematosus</strong></td>
</tr>
</tbody>
</table>

Status since the latest results announcement on 25 July 2019.
YTD and Q3 2019: continued strong sales growth
17% sales growth YTD with new medicines growing at 72%

New medicines remain the key sales drivers

YTD 2019: +$3.0bn
incremental sales of new medicines compared to YTD 2018

Changes (product sales growth) at CER.
### YTD 2019: sales growth across all main therapy areas

Double-digit growth across all therapy areas, Emerging markets

<table>
<thead>
<tr>
<th>Product sales</th>
<th>Q3 2019 $m</th>
<th>% change</th>
<th>% product sales</th>
<th>YTD 2019 $m</th>
<th>% change</th>
<th>% product sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncology</td>
<td>2,334</td>
<td>48</td>
<td>38</td>
<td>6,393</td>
<td>54</td>
<td>37</td>
</tr>
<tr>
<td>New CVRM</td>
<td>1,113</td>
<td>11</td>
<td>18</td>
<td>3,207</td>
<td>14</td>
<td>19</td>
</tr>
<tr>
<td>Respiratory</td>
<td>1,319</td>
<td>18</td>
<td>22</td>
<td>3,854</td>
<td>13</td>
<td>22</td>
</tr>
<tr>
<td>Other medicines</td>
<td>1,366</td>
<td>(7)</td>
<td>22</td>
<td>3,861</td>
<td>(12)</td>
<td>22</td>
</tr>
<tr>
<td>Emerging markets</td>
<td>2,123</td>
<td>29</td>
<td>35</td>
<td>6,074</td>
<td>26</td>
<td>35</td>
</tr>
<tr>
<td>- EMs ex China</td>
<td>839</td>
<td>15</td>
<td>14</td>
<td>2,382</td>
<td>12</td>
<td>14</td>
</tr>
<tr>
<td>- China</td>
<td>1,283</td>
<td>40</td>
<td>21</td>
<td>3,691</td>
<td>37</td>
<td>21</td>
</tr>
</tbody>
</table>

Absolute values at actual exchange rates; changes at CER.
Leader in sustainability
Healthy Heart Africa’s fifth anniversary

• **Access to Healthcare: Healthy Heart Africa**
  Since the launch in 2014, identified over two million elevated high blood-pressure readings

• **2019 Dow Jones Sustainability Indices**
  Recognised as one of the leading companies in the pharmaceuticals industry

• **FTSE4Good Index Series**
  Ranking in the 94th percentile of the healthcare industry

Healthy Heart Africa has trained over 6,300 healthcare workers
Agenda

Overview

Oncology

BioPharmaceuticals, Emerging markets

Finance

Pipeline update, news flow

Closing and Q&A
Oncology: continuing to expand benefits to increasingly more patients from a focused portfolio of standard-of-care medicines

Growth of 54% in YTD 2019

New medicines Tagrisso, Imfinzi, Lynparza and Calquence added $2.3bn in YTD 2019

- **Tagrisso**: global expansion in 1st-line use continued
- **Imfinzi**: continued US growth; ex-US accelerated
- **Lynparza**: further consolidating global PARP$^1$ leadership
- **Faslodex**: loss of exclusivity in the US; erosion picked up
- **Calquence**: strongest quarter since launch

Absolute values and changes at CER and for YTD 2019, unless otherwise stated.

1. Poly-ADP ribose polymerase (inhibitor).
Lung cancer: Tagrisso
1st-line standard of care in US and JP; roll-out continued elsewhere

Strong performance in all markets: +86% in YTD 2019

US +57% (39% of total)
Continued sequential growth despite high adoption. About half of sequential growth from inventory movements, gross-to-net adjustments

Established RoW +156%
JP (+145%): highest global adoption (~75% of new patients); anticipated 15% price reduction in Nov. 2019 (sales reaching ¥35bn)

Europe +61%
Growth driven by DE, FR, IT, rest of Europe. Ongoing 1st-line launches in many countries with reimbursement decisions to stretch into 2020

Emerging markets +120%
Solid 2nd-line penetration in many markets, including China after NRDL\(^1\) listing. 1st-line regulatory approvals increasing; reimbursement to come

Worldwide approvals: 87 countries (2nd-line use) and 78 countries (1st-line use)

Absolute values at actual exchange rates; changes at CER and for YTD 2019, unless otherwise stated.

1. National Reimbursement Drug List.
Lung cancer: Imfinzi
Continued US growth; progress outside US accelerated

US peak sales are expected at >$1bn p.a.

PACIFIC (consolidation treatment in unresectable, Stage III NSCLC) becoming new SoC

- Worldwide approvals: 53 countries
- US $759m (73% of total)
  >65% adoption post CRT with CRT rate among unresectable patients increased to ~65%
- Global use expanding; ex-US $286m
  Top-5 EU; launched with increasing access, reimbursement
  JP ($149m): strong uptake;
  >60% adoption post CRT

US patient infusions continued to increase

Source: proprietary market research.

2. Chemoradiotherapy; a combination of chemotherapy and radiotherapy.

Absolute values at actual exchange rates.
Lynparza
The leading PARP inhibitor globally treating the most patients

Eight quarters of strong growth: +98% in YTD 2019

Leading PARP inhibitor approved in 65 countries in ovarian and in 44 countries in breast cancer

- **US +86%** (51% of total)
  Growth driven by increasing use in 1st-line BRCAm ovarian cancer (SOLO-1 trial)

- **Established RoW +207%**
  JP ($91m): fast/high uptake in ovarian cancer; some offset from Ryotanki lift

- **Europe +61%**
  Increased adoption of broad 2nd-line use and tablets. Breast cancer and SOLO-1 indications launching; lower overall adoption across markets

- **Emerging markets +227%**
  CN: strong launch in ovarian cancer

---

1. Ryotanki: regulation in Japan that restricts prescriptions for medicines in their first year on the market to just two weeks. It lifted in Q2 2019.

Absolute values at actual exchange rates; changes at CER and for YTD 2019, unless otherwise stated.
BioPharmaceuticals: New CVRM and Respiratory

Increasing growth across all major medicines

- **Farxiga**: strong global position in growing class with unique CV data. Data obtained in HF will expand beyond diabetes
- **Brilinta**: global growth continued
- **Fasenra**: strong US, EU and JP launches; market leader of novel biologic medicines in new patients where launched
- **Symbicort/Pulmicort**: solid and growing, global inhaled respiratory business with *Breztri* now launched (JP)
- **Lokelma**: EU, US launches underway with first sales recorded

Absolute values and changes at CER and for YTD 2019, unless otherwise stated.
BioPharmaceuticals: New CVRM

Blockbusters Farxiga and Brilinta continued global growth

Steady Diabetes growth driven by Farxiga
SGLT2\(^1\) the fastest-growing class of oral antidiabetics

- **Farxiga +17%**
  US (-6%): volume growth in growing SGLT2 class offset by impact from Medicare Part D gross-to-net adjustments and January formulary change

- **Lokelma** (hyperkalaemia)
  Launch in Europe and US; encouraging initial uptake

Ex-US (65% of total): accelerating SGLT2 class growth. Europe (+26%), Emerging markets (+50%)

- **Brilinta +26%**: growth across all major regions; benefit of Chinese NRDL inclusion in 2017 still seen

Other: Byetta Onglyza Bydureon Farxiga

1. Sodium-glucose co-transporter 2. Absolute values at actual exchange rates; changes at CER and for YTD 2019, unless otherwise stated.
BioPharmaceuticals: Respiratory
Sales growth 13% with *Fasenra* and *Pulmicort* leading

**Respiratory delivered strong performance**

Performance differentiated by portfolio mix across geographies

- **US +15%**  
  *Symbicort* (-11%); quarterly growth and holding volume against competitor/generics to competitor

- **Europe -6%**  
  Lower *Symbicort* volume in competitive markets

- **Established RoW -2%**  
  JP (+7%): *Fasenra* growth offset transfer of *Symbicort* distribution

- **Emerging markets +31%**  
  Strong *Pulmicort* and *Symbicort*

*Fasenra* now approved in 50 countries, reimbursed in 32 with early-access programmes in 11

- **US $343m**  
  Leading novel biologic medicine in new-patient volume share

- **Europe $81m**  
  Leading new biologic in GE; leading biologic overall in FR, IT in new-patient market share

- **Japan $62m**  
  Leading biologic overall in new-patient market share (>40%)

Source: IQVIA, other market research.

*Other Symbicort Pulmicort Fasenra*  
Absolute values at actual exchange rates; changes at CER and for YTD 2019, unless otherwise stated.
Emerging markets
Broad-based performance from diverse portfolio of countries

Total EMs +26% - ex-China EMs +12% - China +37%
Diversified growth: AP¹ +9% - MEA² +11% - LA³ +13% - Russia +53%

Sales continued to grow ahead of the long-term ambition of mid to high single-digit growth

- New medicines +86%
  22% of total sales; adding $0.7bn in incremental sales

- Therapy areas
  Oncology +51%: Tagrisso ($553m)
  New CVRM +46%: Forxiga (+50%); Brilinta (+59%)
  Respiratory +31%: Pulmicort (+29%, $845m); Symbicort (+18%, $401m)

Other developments: China NRDL

Preliminary update (final list in Q4 2019)
- Adds Kombiglyze; reimbursement restriction removed for some respiratory medicines, incl. Symbicort
- Other medicines under negotiations

Absolute values at actual exchange rates; changes at CER and for YTD 2019, unless otherwise stated.
Agenda

Overview

Oncology

BioPharmaceuticals, Emerging markets

Finance

Pipeline update, news flow

Closing and Q&A
# Reported profit and loss

<table>
<thead>
<tr>
<th></th>
<th>YTD 2019 $m</th>
<th>% change</th>
<th>% total revenue</th>
<th>Q3 2019 $m</th>
<th>% change</th>
<th>% total revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Product sales</strong></td>
<td>17,315</td>
<td>17</td>
<td>98</td>
<td>6,132</td>
<td>18</td>
<td>96</td>
</tr>
<tr>
<td><strong>Collaboration revenue</strong></td>
<td>405</td>
<td>6</td>
<td>2</td>
<td>274</td>
<td>278</td>
<td>4</td>
</tr>
<tr>
<td><strong>Total revenue</strong></td>
<td>17,720</td>
<td>17</td>
<td>100</td>
<td>6,406</td>
<td>22</td>
<td>100</td>
</tr>
<tr>
<td><strong>Gross margin</strong></td>
<td></td>
<td>79.5%</td>
<td></td>
<td>78.0%</td>
<td>(0.1) pp</td>
<td></td>
</tr>
<tr>
<td><strong>Operating expenses</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- <strong>R&amp;D expenses</strong></td>
<td>3,968</td>
<td>5</td>
<td>22</td>
<td>1,346</td>
<td>8</td>
<td>21</td>
</tr>
<tr>
<td>- <strong>SG&amp;A expenses</strong></td>
<td>8,656</td>
<td>20</td>
<td>49</td>
<td>3,199</td>
<td>34</td>
<td>50</td>
</tr>
<tr>
<td><strong>Other operating income</strong></td>
<td>1,041</td>
<td>(31)</td>
<td>6</td>
<td>335</td>
<td>(23)</td>
<td>5</td>
</tr>
<tr>
<td><strong>Operating profit</strong></td>
<td>2,347</td>
<td>3</td>
<td>13</td>
<td>757</td>
<td>(13)</td>
<td>12</td>
</tr>
<tr>
<td><strong>Tax rate</strong></td>
<td></td>
<td>27%</td>
<td></td>
<td></td>
<td>32%</td>
<td></td>
</tr>
</tbody>
</table>

**EPS**

|             | $0.79       | (15)     | $0.23           | (38)        |

1. Includes distribution expenses  
2. Percentage points.  
Absolute values at actual exchange rates; changes at CER.  
Gross margin reflects gross profit derived from product sales, divided by product sales.
## Core profit and loss

<table>
<thead>
<tr>
<th></th>
<th>YTD 2019 $m</th>
<th>% change</th>
<th>% total revenue</th>
<th>Q3 2019 $m</th>
<th>% change</th>
<th>% total revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product sales</td>
<td>17,315</td>
<td>17</td>
<td>98</td>
<td>6,132</td>
<td>18</td>
<td>96</td>
</tr>
<tr>
<td>Collaboration revenue</td>
<td>405</td>
<td>6</td>
<td>2</td>
<td>274</td>
<td>278</td>
<td>4</td>
</tr>
<tr>
<td>Total revenue</td>
<td>17,720</td>
<td>17</td>
<td>100</td>
<td>6,406</td>
<td>22</td>
<td>100</td>
</tr>
<tr>
<td>Gross margin</td>
<td>80.6%</td>
<td>0.8 pp</td>
<td></td>
<td>79.4%</td>
<td>- pp</td>
<td></td>
</tr>
<tr>
<td>Operating expenses¹</td>
<td>10,537</td>
<td>6</td>
<td>59</td>
<td>3,615</td>
<td>9</td>
<td>56</td>
</tr>
<tr>
<td>- R&amp;D expenses</td>
<td>3,826</td>
<td>4</td>
<td>22</td>
<td>1,321</td>
<td>9</td>
<td>21</td>
</tr>
<tr>
<td>- SG&amp;A expenses</td>
<td>6,464</td>
<td>8</td>
<td>36</td>
<td>2,206</td>
<td>9</td>
<td>34</td>
</tr>
<tr>
<td>Other operating income</td>
<td>1,060</td>
<td>(6)</td>
<td>6</td>
<td>352</td>
<td>(19)</td>
<td>5</td>
</tr>
<tr>
<td>Operating profit</td>
<td>4,891</td>
<td>42</td>
<td>28</td>
<td>1,880</td>
<td>41</td>
<td>29</td>
</tr>
<tr>
<td>Tax rate</td>
<td>22%</td>
<td></td>
<td></td>
<td>23%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS</td>
<td>$2.61</td>
<td>38</td>
<td></td>
<td>$0.99</td>
<td>36</td>
<td></td>
</tr>
</tbody>
</table>

¹ Includes distribution expenses.
Absolute values at actual exchange rates; changes at CER.
Gross margin reflects gross profit derived from product sales, divided by product sales.
Improvement in operating cash flow

**Cash-flow headlines**

**YTD 2019 vs. YTD 2018**

- **Net cash from operating activities**
  $1,594m versus $394m primarily due to improvements in working capital offset by higher taxes paid

- **Cash before financing activities**
  $879m versus $430m, including higher disposal of intangible assets more than offset by purchase of intangible assets

- **Prior business development**
  2019 cash was anticipated to include a number of payments relating to prior business development; majority already settled

**Net debt: $13,298m**

Q4 2018-Q3 2019 EBITDA: $7,205m

Absolute values at actual exchange rates.
Finance priorities

YTD results supportive

Deleveraging / dividend growth
• As cash flow improves, deleveraging and progressive dividend policy

Sales growth
+17%
growth in product sales in YTD 2019

Cash-flow growth
• YTD 2019: improvement in cash flow from operating activities
• 2020: anticipated improvement in cash flow

Operating leverage
• 59% ratio of core operating expenses to total revenue (from 65% YTD2018)
• 42% growth in core operating profit
• 28% core operating profit margin

Changes at CER.
2019 guidance updated and re-confirms the growth outlook

Product sales
Now a low to mid-teens percentage increase\(^1\)

Core EPS
$3.50 to $3.70

\(^1\) Previously, guidance for product sales was for a low double-digit percentage increase. Guidance at CER.
Agenda

Overview

Oncology

BioPharmaceuticals, Emerging markets

Finance

Pipeline update, news flow

Closing and Q&A
Oncology: leadership in lung cancer

Tagrisso and Imfinzi saw continued success

**Tagrisso**

- Phase III FLAURA with overall survival

  - Demonstrated ORR\(^1\), PFS\(^2\), and now OS in 1st-line EGFRm NSCLC

**Imfinzi**

- Phase III CASPIAN trial in SCLC\(^3\)

  - First Phase III data in late-stage disease for Imfinzi, in a new cancer
  - Combo with either cisplatin or carboplatin chemotherapy provides more options for patients

**Confirmed as SoC in 1st-line EGFRm NSCLC**

**Positive OS benefit**

**Upcoming news flow Q4’19/2020**

**Phase III data readouts**

- NSCLC (1st line) (POSEIDON) (Q4)
- Head & neck cancer (1st line) (H1)
- Bladder cancer (1st line) (DANUBE) (H1)
- Neo-adjuvant NSCLC (H2)
- Unresectable, Stage III NSCLC (PACIFIC-2) (H2)
- Liver cancer (1st line) (H2)

**Opportunity to expand benefit of Imfinzi to more patients**

1. Objective response rate.
2. Progression-free survival.
Source: abstract LB05, European Society for Medical Oncology Congress 2019.

**Oncology: leadership in DNA damage response**

**Lynparza use to broaden in 1st-line ovarian cancer and prostate cancer**

- **Phase III PAOLA-1 trial in 1st-line ovarian cancer**
  - PFS primary endpoint in all-comers

- **Phase III PROfound trial in prostate cancer**
  - First positive Phase III trial in biomarker-selected mCRPC

- **Bevacizumab + Lynparza median PFS of >22 months in 1st-line ovarian cancer maintenance use**
  - Safety consistent with previous trials; addition of Lynparza did not impact on bevacizumab tolerability and HR-QoL

- **New treatment option in selected metastatic castration-resistant prostate cancer (mCRPC) after new hormonal medicines**

Source: abstract LBA2, European Society for Medical Oncology Congress 2019.

1. Homologous recombination deficiency.
2. Health-related quality of life.
3. Homologous recombination repair mutations.
4. BRCA 1/2 and ATM mutations with clinically meaningful benefit.

Source: abstract LBA12, European Society for Medical Oncology Congress 2019.
BioPharmaceuticals: New CVRM

Breakthrough heart failure data for Farxiga

**Farxiga**
- T2D CVOT (Phase III DECLARE): regulatory approval (US, EU)
- HF, CKD: Fast Track designation (US)
- T2D: positive opinion (Qtrilmet) (EU)

**Brilinta**
- CAD/T2D (Phase III THEMIS) presented
  - Adding Brilinta reduced MACE\(^1\) by 10%
  - 15% relative risk reduction in PCI\(^2\) patients

**Farxiga in T2D and non-T2D HF patients with more data to come**

**CV death/HF hospitalisation/HF urgent visit**

- HR 0.74 (0.65,0.85)
- p=0.00001
- NNT=21

**Roxadustat**
- Anaemia of CKD; NDD: regulatory approval (CN)
- Data presentation at ASN\(^4\) 2019
  - Full data from Phase III ROCKIES and OLYMPUS trials
  - Pooled CV safety data from eight Phase III trials

---

1. Major adverse cardiovascular events.
2. Percutaneous coronary intervention.
3. Heart failure with preserved ejection fraction.

Source: abstracts 2097 and 2098, European Society of Cardiology 2019.
BioPharmaceuticals: Respiratory
Recent progress in COPD and lupus (SLE)

Regulatory and other milestones

**Fasenra**
- Severe eosinophilic asthma - auto-injector and self-administration: regulatory approval (US)
- Eosinophilic oesophagitis: Orphan Drug Designation (US)

Further progress in lifecycle programme

**Breztri/PT010 in COPD**
- Phase III ETHOS trial
  - Statistically significant reduction in the rate of moderate/severe exacerbations
  - Safety profile confirmed
  - ETHOS will be shared with the US FDA to address complete response letter based on only one trial originally submitted (Phase III KRONOS trial)

**Breztri approved and launched in Japan**

**Anifrolumab positive in 2nd Phase III lupus (SLE) trial**
- Statistically significant and clinically meaningful reduction in disease activity
- Positive BICLA\(^1\) response in Phase III TULIP 2 was consistent with pre-specified analysis of Phase III TULIP 1
- Data presentation at ACR 2019\(^3\)
- Phase II for subcutaneous formulation completed; Phase II for lupus nephritis in 2021

Regulatory submission targeted for H2 2020

---

1. BILAG\(^2\)-based composite lupus assessment.
2. British Isles lupus assessment group.
### Oncology

<table>
<thead>
<tr>
<th>Drug</th>
<th>Disease</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>capivasertib (AKT&lt;sup&gt;1&lt;/sup&gt; inhibitor)</td>
<td>breast, prostate cancers</td>
<td>III</td>
</tr>
<tr>
<td>adavosertib (WEE1&lt;sup&gt;2&lt;/sup&gt; inhibitor)</td>
<td>solid tumours</td>
<td>II</td>
</tr>
<tr>
<td>ceralasertib (ATR&lt;sup&gt;3&lt;/sup&gt; inhibitor)</td>
<td>solid tumours / blood cancers</td>
<td>II</td>
</tr>
<tr>
<td>AZD9833 (SRD&lt;sup&gt;4&lt;/sup&gt; oral)</td>
<td>breast cancer</td>
<td></td>
</tr>
<tr>
<td>AZD5991 (MCL1&lt;sup&gt;5&lt;/sup&gt; inhibitor)</td>
<td>blood cancers</td>
<td>I</td>
</tr>
<tr>
<td>AZD2811 (Aurora B inhibitor)</td>
<td>solid tumours / blood cancers</td>
<td>II/I</td>
</tr>
</tbody>
</table>

### New CVRM

<table>
<thead>
<tr>
<th>Drug</th>
<th>Disease</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>trastuzumab deruxtecan (HER2 ADC)</td>
<td>breast, gastric, other - Phase II/III</td>
<td></td>
</tr>
<tr>
<td>monalizumab (NKG2α&lt;sup&gt;6&lt;/sup&gt; mAb&lt;sup&gt;1&lt;/sup&gt;)</td>
<td>head &amp; neck, colorectal</td>
<td>II</td>
</tr>
<tr>
<td>oleclumab (CD73&lt;sup&gt;7&lt;/sup&gt; mAb)</td>
<td>lung, pancreatic cancers</td>
<td>II</td>
</tr>
<tr>
<td>AZD4635 (A2AR&lt;sup&gt;9&lt;/sup&gt; inhibitor)</td>
<td>solid tumours</td>
<td>II</td>
</tr>
<tr>
<td>danvatirsen (STAT3&lt;sup&gt;10&lt;/sup&gt; inhibitor)</td>
<td>bladder, head &amp; neck, lung</td>
<td>I/I</td>
</tr>
<tr>
<td>MED5752 (PD-1/CTLA-4)</td>
<td>solid tumours</td>
<td>I</td>
</tr>
</tbody>
</table>

### Respiratory

<table>
<thead>
<tr>
<th>Drug</th>
<th>Disease</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT027 (SABA/ICS&lt;sup&gt;17&lt;/sup&gt;)</td>
<td>asthma</td>
<td>III</td>
</tr>
<tr>
<td>AZD1402 (IL-4R&lt;sup&gt;18&lt;/sup&gt; antagonist)</td>
<td>asthma</td>
<td>II</td>
</tr>
<tr>
<td>MEDI3506 (IL-33&lt;sup&gt;19&lt;/sup&gt; mAb)</td>
<td>COPD</td>
<td></td>
</tr>
<tr>
<td>AZD0449 (inhaled JAK&lt;sup&gt;20&lt;/sup&gt; inhibitor)</td>
<td>asthma</td>
<td>I</td>
</tr>
<tr>
<td>AZD8154 (inhaled PI3Kδ&lt;sup&gt;21&lt;/sup&gt; inhibitor)</td>
<td>asthma</td>
<td>I</td>
</tr>
<tr>
<td>AZD7594 (inhaled SGRM&lt;sup&gt;22&lt;/sup&gt; modulator)</td>
<td>COPD, asthma</td>
<td>II</td>
</tr>
</tbody>
</table>

### ‘What’s next’: aiming for sustainable sales growth

Rich mid-stage pipeline; selected new molecular entities

1. Protein kinase B
2. Tyrosine kinase WEE1
3. Ataxia telangiectasia and rad3-related kinase
4. Selective oestrogen receptor degrader
5. Induced myeloid leukaemia cell differentiation protein
6. Inhibitory cell surface receptor covalently bound to CD94
7. Monoclonal antibody
8. S<sup>-</sup>nucleotidase
9. Adenosine A2A receptor
10. Signal transducer and activator of transcription 3
11. Glucagon-like peptide-1
12. Non-alcoholic steatohepatitis
13. 5-Lipoxygenase-activating protein
14. Myeloperoxidase
15. Vascular endothelial growth factor A modified messenger RNA
16. Patatin-like phospholipase domain-containing protein 3
17. Short-acting β-agonist/inhaled corticosteroid
18. Interleukin-4 receptor
19. Interleukin-33
20. Janus kinase
21. Phosphoinositide 3-kinase gamma/delta
22. Selective glucocorticoid receptor modulator.
Late-stage pipeline events in the 2019 to 2021 timeframe
Busy news flow continues; underpinning consistent sales growth

<table>
<thead>
<tr>
<th>Q4 2019</th>
<th>H1 2020</th>
<th>H2 2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Imfinzi</strong> - unresectable, Stage III NSCLC (PACIFIC) (CN)</td>
<td><strong>Lynparza</strong> - breast cancer (BRCAm) (CN)</td>
<td><strong>Lynparza</strong> - pancreatic cancer (1L, BRCAm) (EU)</td>
<td>-</td>
</tr>
<tr>
<td><strong>Lynparza</strong> - ovarian cancer (1L, BRCAm) (SOLO-1) (CN)</td>
<td><strong>trastuzumab deruxtecan</strong> - breast cancer (3L+, HER2+) (US, JP)</td>
<td><strong>Lynparza</strong> + cediranib - ovarian cancer (2L)</td>
<td><strong>Imfinzi</strong> - neo-adjuvant NSCLC; adjuvant NSCLC; unresectable, Stage III NSCLC (PACIFIC-2); NSCLC (1L) (PEARL); liver cancer (locoregional)</td>
</tr>
<tr>
<td><strong>Imfinzi</strong> +/treme - NSCLC (1L) (POSEIDON)</td>
<td><strong>Brilinta</strong> - head &amp; neck cancer (1L)</td>
<td><strong>Imfinzi</strong> +/treme - liver cancer (1L)</td>
<td><strong>Imfinzi</strong> - adjuvant breast cancer; prostate cancer (1L, castration-resistant)</td>
</tr>
<tr>
<td><strong>sorafenib</strong> - mild asthma (CN)</td>
<td><strong>Lynparza</strong> - bladder cancer (1L) (DANUBE)</td>
<td><strong>Lynparza</strong> - gastric cancer (HER2+) (JP)</td>
<td><strong>Lynparza</strong> + cediranib - ovarian cancer (2L)</td>
</tr>
<tr>
<td><strong>Rexadustat</strong> - anaemia of CKD (US)</td>
<td><strong>trastuzumab deruxtecan</strong> - gastric cancer (HER2+) (JP)</td>
<td><strong>trastuzumab deruxtecan</strong> - breast cancer (3L, HER2+)</td>
<td><strong>Trastuzumab deruxtecan</strong> +/treme - breast cancer (3L, HER2+); (2L, HER2+); (HER2 low)</td>
</tr>
<tr>
<td><strong>Symbicort</strong> - mild asthma (CN)</td>
<td><strong>Calquence</strong> - CLI (US)</td>
<td><strong>Calquence</strong> - CLI (EU, JP)</td>
<td><strong>Farxiga</strong> - CKD</td>
</tr>
<tr>
<td><strong>Rexadustat</strong> - anaemia of CKD (US)</td>
<td><strong>selumetinib</strong> - neurofibromatosis type 1 (US)</td>
<td><strong>selumetinib</strong> - neurofibromatosis type 1 (EU)</td>
<td><strong>Epanova</strong> - hypertriglyceridaemia CVOT</td>
</tr>
<tr>
<td><strong>Rexadustat</strong> - anaemia of CKD (US)</td>
<td><strong>trastuzumab deruxtecan</strong> - gastric cancer (HER2+) (JP)</td>
<td><strong>trastuzumab deruxtecan</strong> - breast cancer (3L, HER2+)</td>
<td><strong>Epanova</strong> +/treme - anaemia of myelodysplastic syndrome</td>
</tr>
<tr>
<td><strong>Farxiga</strong> - CKD</td>
<td><strong>Calquence</strong> - CLI (US)</td>
<td><strong>Farxiga</strong> - CKD</td>
<td><strong>Farxiga</strong> - CKD</td>
</tr>
<tr>
<td><strong>Symbicort</strong> - mild asthma (CN)</td>
<td><strong>tezepelumab</strong> - severe asthma</td>
<td><strong>tezepelumab</strong> - severe asthma</td>
<td><strong>tezepelumab</strong> - severe asthma</td>
</tr>
</tbody>
</table>

Key Phase III data readouts1

| Status as of 24 October 2019. |
Agenda

Overview

Oncology

BioPharmaceuticals, Emerging markets

Finance

Pipeline update, news flow

Closing and Q&A
YTD and Q3 2019: repeated strong sales growth
Investing in sustainable growth continued on R&D, SG&A

**Product sales** up by 17%; 18% in the third quarter
- Strong performance of new medicines\(^1\) (+72%); $3.0bn incremental sales vs. YTD 2018
- Oncology (+54%), New CVRM\(^2\) (+14%) and Respiratory (+13%)
- Emerging markets (+26%); broad-based performance across EMs

**Total revenue** up by 17%; broadly stable collaboration revenue
**Core operating costs** up by 6%; investing in sustainable growth
**Core operating profit** up by 42%; continuing operating leverage. **Core EPS** $2.61, including 22% tax rate

**Guidance** increased again for product sales; unchanged for core EPS\(^3\) (due to accelerating strategic transition, resulting in anticipated lower total of collaboration revenue and other operating income)

Focus on **cash-flow generation** whilst continuing to invest in high-growth opportunities and rich pipeline

**Pipeline** with unprecedented recent positive news flow; busy 2021 pipeline plans unveiled

---

Absolute values and changes at CER (except core EPS) and for YTD 2019, unless otherwise stated. Guidance at CER.
Use of AstraZeneca conference call, webcast and presentation slides

The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca Materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZeneca Materials in any way. You may not edit, alter, adapt or add to the AstraZeneca Materials in any way, nor combine the AstraZeneca Materials with any other material. You may not download or use the AstraZeneca Materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca Materials. You may not use the AstraZeneca Materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. Telephone + 44 20 3749 5000, www.astrazeneca.com